Drug Approval | June 27, 2022
Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
The TAT-5000 and the TAT-2000 thermometers for professional use by doctors and nurses and the TAT-2000C thermometer for consumer applications are based on a very innovative infrared technology
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Subscribe To Our Newsletter & Stay Updated
